APO Research
Talk to an analyst

APO RESEARCH · REPORT

Focal Segmental Glomerulosclerosis Drug

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Focal Segmental Glomerulosclerosis Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

22 December 2025187 pages

Choose your research edition.

Industry ResearchFocal Segmental Glomerulosclerosis Drug Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Focal Segmental Glomerulosclerosis Drug Industry Growth and Trends Forecast to 203293 pages · $3,450 USDMarket StructureGlobal Focal Segmental Glomerulosclerosis Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032187 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Focal Segmental Glomerulosclerosis Drug Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Focal Segmental Glomerulosclerosis Drug Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Focal Segmental Glomerulosclerosis Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Focal Segmental Glomerulosclerosis Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Focal Segmental Glomerulosclerosis Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Focal Segmental Glomerulosclerosis Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Focal Segmental Glomerulosclerosis Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Focal Segmental Glomerulosclerosis Drug include Takeda, GlaxoSmithKline Plc, Variant Pharmaceuticals Inc, Retrophin Inc, Dimerix Bioscience Pty Ltd and Complexa Inc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Focal Segmental Glomerulosclerosis Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Focal Segmental Glomerulosclerosis Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Focal Segmental Glomerulosclerosis Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Focal Segmental Glomerulosclerosis Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Focal Segmental Glomerulosclerosis Drug Segment by Company

Takeda

GlaxoSmithKline Plc

Variant Pharmaceuticals Inc

Retrophin Inc

Dimerix Bioscience Pty Ltd

Complexa Inc

Focal Segmental Glomerulosclerosis Drug Segment by Type

Losmapimod

SHP-627

Sparsentan

TM-5484

Others

Focal Segmental Glomerulosclerosis Drug Segment by Application

Clinic

Hospital

Research Center

Others

Focal Segmental Glomerulosclerosis Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Focal Segmental Glomerulosclerosis Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Focal Segmental Glomerulosclerosis Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Focal Segmental Glomerulosclerosis Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Focal Segmental Glomerulosclerosis Drug market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Focal Segmental Glomerulosclerosis Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Focal Segmental Glomerulosclerosis Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Focal Segmental Glomerulosclerosis Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Focal Segmental Glomerulosclerosis Drug Industry Trends Table 2. Focal Segmental Glomerulosclerosis Drug Industry Drivers Table 3. Focal Segmental Glomerulosclerosis Drug Industry Opportunities and Challenges Table 4. Focal Segmental Glomerulosclerosis Drug Industry Restraints Table 5. Global Focal Segmental Glomerulosclerosis Drug Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Focal Segmental Glomerulosclerosis Drug Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Focal Segmental Glomerulosclerosis Drug Sales by Manufacturers (k units) & (2021-2026) Table 8. Global Focal Segmental Glomerulosclerosis Drug Sales Market Share by Manufacturers Table 9. Global Focal Segmental Glomerulosclerosis Drug Average Sales Price (US$/unit) of Manufacturers (2021-2026) Table 10. Global Focal Segmental Glomerulosclerosis Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Focal Segmental Glomerulosclerosis Drug Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Focal Segmental Glomerulosclerosis Drug Manufacturers, Product Type & Application Table 13. Global Focal Segmental Glomerulosclerosis Drug Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Focal Segmental Glomerulosclerosis Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Losmapimod Table 17. Major Manufacturers of SHP-627 Table 18. Major Manufacturers of Sparsentan Table 19. Major Manufacturers of TM-5484 Table 20. Major Manufacturers of Others Table 21. Global Focal Segmental Glomerulosclerosis Drug Sales by Type 2021 VS 2025 VS 2032 (k units) Table 22. Global Focal Segmental Glomerulosclerosis Drug Sales by Type (2021-2026) & (k units) Table 23. Global Focal Segmental Glomerulosclerosis Drug Sales by Type (2027-2032) & (k units) Table 24. Global Focal Segmental Glomerulosclerosis Drug Sales Market Share by Type (2021-2026) Table 25. Global Focal Segmental Glomerulosclerosis Drug Sales Market Share by Type (2027-2032) Table 26. Global Focal Segmental Glomerulosclerosis Drug Revenue by Type 2021 VS 2025 VS 2032 (k units) Table 27. Global Focal Segmental Glomerulosclerosis Drug Revenue by Type (2021-2026) & (k units) Table 28. Global Focal Segmental Glomerulosclerosis Drug Revenue by Type (2027-2032) & (k units) Table 29. Global Focal Segmental Glomerulosclerosis Drug Revenue Market Share by Type (2021-2026) Table 30. Global Focal Segmental Glomerulosclerosis Drug Revenue Market Share by Type (2027-2032) Table 31. Major Manufacturers of Clinic Table 32. Major Manufacturers of Hospital Table 33. Major Manufacturers of Research Center Table 34. Major Manufacturers of Others Table 35. Global Focal Segmental Glomerulosclerosis Drug Sales by Application 2021 VS 2025 VS 2032 (k units) Table 36. Global Focal Segmental Glomerulosclerosis Drug Sales by Application (2021-2026) & (k units) Table 37. Global Focal Segmental Glomerulosclerosis Drug Sales by Application (2027-2032) & (k units) Table 38. Global Focal Segmental Glomerulosclerosis Drug Sales Market Share by Application (2021-2026) Table 39. Global Focal Segmental Glomerulosclerosis Drug Sales Market Share by Application (2027-2032) Table 40. Global Focal Segmental Glomerulosclerosis Drug Revenue by Application 2021 VS 2025 VS 2032 (k units) Table 41. Global Focal Segmental Glomerulosclerosis Drug Revenue by Application (2021-2026) & (k units) Table 42. Global Focal Segmental Glomerulosclerosis Drug Revenue by Application (2027-2032) & (k units) Table 43. Global Focal Segmental Glomerulosclerosis Drug Revenue Market Share by Application (2021-2026) Table 44. Global Focal Segmental Glomerulosclerosis Drug Revenue Market Share by Application (2027-2032) Table 45. Global Focal Segmental Glomerulosclerosis Drug Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 46. Global Focal Segmental Glomerulosclerosis Drug Sales by Region (2021-2026) & (k units) Table 47. Global Focal Segmental Glomerulosclerosis Drug Sales Market Share by Region (2021-2026) Table 48. Global Focal Segmental Glomerulosclerosis Drug Sales Forecasted by Region (2027-2032) & (k units) Table 49. Global Focal Segmental Glomerulosclerosis Drug Sales Forecasted Market Share by Region (2027-2032) Table 50. North America Focal Segmental Glomerulosclerosis Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 51. North America Focal Segmental Glomerulosclerosis Drug Sales by Country (2021-2026) & (k units) Table 52. North America Focal Segmental Glomerulosclerosis Drug Sales by Country (2027-2032) & (k units) Table 53. Europe Focal Segmental Glomerulosclerosis Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 54. Europe Focal Segmental Glomerulosclerosis Drug Sales by Country (2021-2026) & (k units) Table 55. Europe Focal Segmental Glomerulosclerosis Drug Sales by Country (2027-2032) & (k units) Table 56. Asia Pacific Focal Segmental Glomerulosclerosis Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 57. Asia Pacific Focal Segmental Glomerulosclerosis Drug Sales by Country (2021-2026) & (k units) Table 58. Asia Pacific Focal Segmental Glomerulosclerosis Drug Sales by Country (2027-2032) & (k units) Table 59. South America, Middle East and Africa Focal Segmental Glomerulosclerosis Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 60. South America, Middle East and Africa Focal Segmental Glomerulosclerosis Drug Sales by Country (2021-2026) & (k units) Table 61. South America, Middle East and Africa Focal Segmental Glomerulosclerosis Drug Sales by Country (2027-2032) & (k units) Table 62. Global Focal Segmental Glomerulosclerosis Drug Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 63. Global Focal Segmental Glomerulosclerosis Drug Revenue by Region (2021-2026) & (US$ Million) Table 64. Global Focal Segmental Glomerulosclerosis Drug Revenue by Region (2027-2032) & (US$ Million) Table 65. Global Focal Segmental Glomerulosclerosis Drug Revenue Market Share by Region (2021-2026) Table 66. Global Focal Segmental Glomerulosclerosis Drug Revenue Market Share by Region (2027-2032) Table 67. Takeda Company Information Table 68. Takeda Business Overview Table 69. Takeda Focal Segmental Glomerulosclerosis Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Takeda Focal Segmental Glomerulosclerosis Drug Product Portfolio Table 71. Takeda Recent Development Table 72. GlaxoSmithKline Plc Company Information Table 73. GlaxoSmithKline Plc Business Overview Table 74. GlaxoSmithKline Plc Focal Segmental Glomerulosclerosis Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. GlaxoSmithKline Plc Focal Segmental Glomerulosclerosis Drug Product Portfolio Table 76. GlaxoSmithKline Plc Recent Development Table 77. Variant Pharmaceuticals Inc Company Information Table 78. Variant Pharmaceuticals Inc Business Overview Table 79. Variant Pharmaceuticals Inc Focal Segmental Glomerulosclerosis Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Variant Pharmaceuticals Inc Focal Segmental Glomerulosclerosis Drug Product Portfolio Table 81. Variant Pharmaceuticals Inc Recent Development Table 82. Retrophin Inc Company Information Table 83. Retrophin Inc Business Overview Table 84. Retrophin Inc Focal Segmental Glomerulosclerosis Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. Retrophin Inc Focal Segmental Glomerulosclerosis Drug Product Portfolio Table 86. Retrophin Inc Recent Development Table 87. Dimerix Bioscience Pty Ltd Company Information Table 88. Dimerix Bioscience Pty Ltd Business Overview Table 89. Dimerix Bioscience Pty Ltd Focal Segmental Glomerulosclerosis Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. Dimerix Bioscience Pty Ltd Focal Segmental Glomerulosclerosis Drug Product Portfolio Table 91. Dimerix Bioscience Pty Ltd Recent Development Table 92. Complexa Inc Company Information Table 93. Complexa Inc Business Overview Table 94. Complexa Inc Focal Segmental Glomerulosclerosis Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 95. Complexa Inc Focal Segmental Glomerulosclerosis Drug Product Portfolio Table 96. Complexa Inc Recent Development Table 97. Key Raw Materials Table 98. Raw Materials Key Suppliers Table 99. Focal Segmental Glomerulosclerosis Drug Distributors List Table 100. Focal Segmental Glomerulosclerosis Drug Customers List Table 101. Research Programs/Design for This Report Table 102. Authors List of This Report Table 103. Secondary Sources Table 104. Primary Sources List of Figures Figure 1. Focal Segmental Glomerulosclerosis Drug Product Image Figure 2. Global Focal Segmental Glomerulosclerosis Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Focal Segmental Glomerulosclerosis Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Focal Segmental Glomerulosclerosis Drug Sales (2021-2032) & (k units) Figure 5. Global Focal Segmental Glomerulosclerosis Drug Average Price (US$/unit) & (2021-2032) Figure 6. Global Top 5 and 10 Focal Segmental Glomerulosclerosis Drug Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Losmapimod Image Figure 9. SHP-627 Image Figure 10. Sparsentan Image Figure 11. TM-5484 Image Figure 12. Others Image Figure 13. Global Focal Segmental Glomerulosclerosis Drug Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 14. Global Focal Segmental Glomerulosclerosis Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 15. Global Focal Segmental Glomerulosclerosis Drug Sales Market Share by Type (2021-2032) Figure 16. Global Focal Segmental Glomerulosclerosis Drug Revenue by Type (2021 VS 2025 VS 2032) & (k units) Figure 17. Global Focal Segmental Glomerulosclerosis Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Focal Segmental Glomerulosclerosis Drug Revenue Market Share by Type (2021-2032) Figure 19. Clinic Image Figure 20. Hospital Image Figure 21. Research Center Image Figure 22. Others Image Figure 23. Global Focal Segmental Glomerulosclerosis Drug Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 24. Global Focal Segmental Glomerulosclerosis Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 25. Global Focal Segmental Glomerulosclerosis Drug Sales Market Share by Application (2021-2032) Figure 26. Global Focal Segmental Glomerulosclerosis Drug Revenue by Application (2021 VS 2025 VS 2032) & (k units) Figure 27. Global Focal Segmental Glomerulosclerosis Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 28. Global Focal Segmental Glomerulosclerosis Drug Revenue Market Share by Application (2021-2032) Figure 29. North America Focal Segmental Glomerulosclerosis Drug Sales and Growth Rate (2021-2032) & (k units) Figure 30. North America Focal Segmental Glomerulosclerosis Drug Sales Market Share by Country (2021-2032) Figure 31. U.S. Focal Segmental Glomerulosclerosis Drug Sales and Growth Rate (2021-2032) & (k units) Figure 32. Canada Focal Segmental Glomerulosclerosis Drug Sales and Growth Rate (2021-2032) & (k units) Figure 33. Mexico Focal Segmental Glomerulosclerosis Drug Sales and Growth Rate (2021-2032) & (k units) Figure 34. Europe Focal Segmental Glomerulosclerosis Drug Sales and Growth Rate (2021-2032) & (k units) Figure 35. Europe Focal Segmental Glomerulosclerosis Drug Sales Market Share by Country (2021-2032) Figure 36. Germany Focal Segmental Glomerulosclerosis Drug Sales and Growth Rate (2021-2032) & (k units) Figure 37. France Focal Segmental Glomerulosclerosis Drug Sales and Growth Rate (2021-2032) & (k units) Figure 38. U.K. Focal Segmental Glomerulosclerosis Drug Sales and Growth Rate (2021-2032) & (k units) Figure 39. Italy Focal Segmental Glomerulosclerosis Drug Sales and Growth Rate (2021-2032) & (k units) Figure 40. Netherlands Focal Segmental Glomerulosclerosis Drug Sales and Growth Rate (2021-2032) & (k units) Figure 41. Asia Pacific Focal Segmental Glomerulosclerosis Drug Sales and Growth Rate (2021-2032) & (k units) Figure 42. Asia Pacific Focal Segmental Glomerulosclerosis Drug Sales Market Share by Country (2021-2032) Figure 43. China Focal Segmental Glomerulosclerosis Drug Sales and Growth Rate (2021-2032) & (k units) Figure 44. Japan Focal Segmental Glomerulosclerosis Drug Sales and Growth Rate (2021-2032) & (k units) Figure 45. South Korea Focal Segmental Glomerulosclerosis Drug Sales and Growth Rate (2021-2032) & (k units) Figure 46. Southeast Asia Focal Segmental Glomerulosclerosis Drug Sales and Growth Rate (2021-2032) & (k units) Figure 47. India Focal Segmental Glomerulosclerosis Drug Sales and Growth Rate (2021-2032) & (k units) Figure 48. Australia Focal Segmental Glomerulosclerosis Drug Sales and Growth Rate (2021-2032) & (k units) Figure 49. South America, Middle East and Africa Focal Segmental Glomerulosclerosis Drug Sales and Growth Rate (2021-2032) & (k units) Figure 50. South America, Middle East and Africa Focal Segmental Glomerulosclerosis Drug Sales Market Share by Country (2021-2032) Figure 51. Brazil Focal Segmental Glomerulosclerosis Drug Sales and Growth Rate (2021-2032) & (k units) Figure 52. South Africa Focal Segmental Glomerulosclerosis Drug Sales and Growth Rate (2021-2032) & (k units) Figure 53. Saudi Arabia Focal Segmental Glomerulosclerosis Drug Sales and Growth Rate (2021-2032) & (k units) Figure 54. Turkey Focal Segmental Glomerulosclerosis Drug Sales and Growth Rate (2021-2032) & (k units) Figure 55. Argentina Focal Segmental Glomerulosclerosis Drug Sales and Growth Rate (2021-2032) & (k units) Figure 56. UAE Focal Segmental Glomerulosclerosis Drug Sales and Growth Rate (2021-2032) & (k units) Figure 57. Egypt Focal Segmental Glomerulosclerosis Drug Sales and Growth Rate (2021-2032) & (k units) Figure 58. Chile Focal Segmental Glomerulosclerosis Drug Sales and Growth Rate (2021-2032) & (k units) Figure 59. Global Focal Segmental Glomerulosclerosis Drug Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Global Focal Segmental Glomerulosclerosis Drug Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 61. North America Focal Segmental Glomerulosclerosis Drug Revenue (2021-2032) & (US$ Million) Figure 62. North America Focal Segmental Glomerulosclerosis Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Europe Focal Segmental Glomerulosclerosis Drug Revenue (2021-2032) & (US$ Million) Figure 64. Europe Focal Segmental Glomerulosclerosis Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Asia-Pacific Focal Segmental Glomerulosclerosis Drug Revenue (2021-2032) & (US$ Million) Figure 66. Asia-Pacific Focal Segmental Glomerulosclerosis Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. South America, Middle East and Africa Focal Segmental Glomerulosclerosis Drug Revenue (2021-2032) & (US$ Million) Figure 68. South America, Middle East and Africa Focal Segmental Glomerulosclerosis Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 69. Focal Segmental Glomerulosclerosis Drug Value Chain Figure 70. Manufacturing Cost Structure Figure 71. Focal Segmental Glomerulosclerosis Drug Production Mode & Process Figure 72. Direct Comparison with Distribution Share Figure 73. Distributors Profiles Figure 74. Years Considered Figure 75. Research Process Figure 76. Key Executives Interviewed

Scope & coverage.

Types
  • Losmapimod
  • SHP-627
  • Sparsentan
  • TM-5484
  • Others
Applications
  • Clinic
  • Hospital
  • Research Center
  • Others
Companies covered
  • Takeda
  • GlaxoSmithKline Plc
  • Variant Pharmaceuticals Inc
  • Retrophin Inc
  • Dimerix Bioscience Pty Ltd
  • Complexa Inc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Focal Segmental Glomerulosclerosis Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Focal Segmental Glomerulosclerosis Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Focal Segmental Glomerulosclerosis Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Focal Segmental Glomerulosclerosis Drug Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Focal Segmental Glomerulosclerosis Drug Market Dynamics
  1. 2.1 Focal Segmental Glomerulosclerosis Drug Industry Trends
  2. 2.2 Focal Segmental Glomerulosclerosis Drug Industry Drivers
  3. 2.3 Focal Segmental Glomerulosclerosis Drug Industry Opportunities and Challenges
  4. 2.4 Focal Segmental Glomerulosclerosis Drug Industry Restraints
3 Focal Segmental Glomerulosclerosis Drug Market by Manufacturers
  1. 3.1 Global Focal Segmental Glomerulosclerosis Drug Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Focal Segmental Glomerulosclerosis Drug Sales by Manufacturers (2021-2026)
  3. 3.3 Global Focal Segmental Glomerulosclerosis Drug Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Focal Segmental Glomerulosclerosis Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Focal Segmental Glomerulosclerosis Drug Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Focal Segmental Glomerulosclerosis Drug Manufacturers, Product Type & Application
  7. 3.7 Global Focal Segmental Glomerulosclerosis Drug Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Focal Segmental Glomerulosclerosis Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Focal Segmental Glomerulosclerosis Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Focal Segmental Glomerulosclerosis Drug Tier 1, Tier 2, and Tier 3
4 Focal Segmental Glomerulosclerosis Drug Market by Type
  1. 4.1 Focal Segmental Glomerulosclerosis Drug Type Introduction
  2. 4.1.1 Losmapimod
  3. 4.1.2 SHP-627
  4. 4.1.3 Sparsentan
  5. 4.1.4 TM-5484
  6. 4.1.5 Others
  7. 4.2 Global Focal Segmental Glomerulosclerosis Drug Sales by Type
  8. 4.2.1 Global Focal Segmental Glomerulosclerosis Drug Sales by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Focal Segmental Glomerulosclerosis Drug Sales by Type (2021-2032)
  10. 4.2.3 Global Focal Segmental Glomerulosclerosis Drug Sales Market Share by Type (2021-2032)
  11. 4.3 Global Focal Segmental Glomerulosclerosis Drug Revenue by Type
  12. 4.3.1 Global Focal Segmental Glomerulosclerosis Drug Revenue by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Focal Segmental Glomerulosclerosis Drug Revenue by Type (2021-2032)
  14. 4.3.3 Global Focal Segmental Glomerulosclerosis Drug Revenue Market Share by Type (2021-2032)
5 Focal Segmental Glomerulosclerosis Drug Market by Application
  1. 5.1 Focal Segmental Glomerulosclerosis Drug Application Introduction
  2. 5.1.1 Clinic
  3. 5.1.2 Hospital
  4. 5.1.3 Research Center
  5. 5.1.4 Others
  6. 5.2 Global Focal Segmental Glomerulosclerosis Drug Sales by Application
  7. 5.2.1 Global Focal Segmental Glomerulosclerosis Drug Sales by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Focal Segmental Glomerulosclerosis Drug Sales by Application (2021-2032)
  9. 5.2.3 Global Focal Segmental Glomerulosclerosis Drug Sales Market Share by Application (2021-2032)
  10. 5.3 Global Focal Segmental Glomerulosclerosis Drug Revenue by Application
  11. 5.3.1 Global Focal Segmental Glomerulosclerosis Drug Revenue by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Focal Segmental Glomerulosclerosis Drug Revenue by Application (2021-2032)
  13. 5.3.3 Global Focal Segmental Glomerulosclerosis Drug Revenue Market Share by Application (2021-2032)
6 Global Focal Segmental Glomerulosclerosis Drug Sales by Region
  1. 6.1 Global Focal Segmental Glomerulosclerosis Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Focal Segmental Glomerulosclerosis Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Focal Segmental Glomerulosclerosis Drug Sales by Region (2021-2026)
  4. 6.2.2 Global Focal Segmental Glomerulosclerosis Drug Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Focal Segmental Glomerulosclerosis Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Focal Segmental Glomerulosclerosis Drug Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Focal Segmental Glomerulosclerosis Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Focal Segmental Glomerulosclerosis Drug Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Focal Segmental Glomerulosclerosis Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Focal Segmental Glomerulosclerosis Drug Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Focal Segmental Glomerulosclerosis Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Focal Segmental Glomerulosclerosis Drug Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Focal Segmental Glomerulosclerosis Drug Revenue by Region
  1. 7.1 Global Focal Segmental Glomerulosclerosis Drug Revenue by Region
  2. 7.1.1 Global Focal Segmental Glomerulosclerosis Drug Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Focal Segmental Glomerulosclerosis Drug Revenue by Region (2021-2026)
  4. 7.1.3 Global Focal Segmental Glomerulosclerosis Drug Revenue by Region (2027-2032)
  5. 7.1.4 Global Focal Segmental Glomerulosclerosis Drug Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Focal Segmental Glomerulosclerosis Drug Revenue (2021-2032)
  8. 7.2.2 North America Focal Segmental Glomerulosclerosis Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Focal Segmental Glomerulosclerosis Drug Revenue (2021-2032)
  11. 7.3.2 Europe Focal Segmental Glomerulosclerosis Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Focal Segmental Glomerulosclerosis Drug Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Focal Segmental Glomerulosclerosis Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Focal Segmental Glomerulosclerosis Drug Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Focal Segmental Glomerulosclerosis Drug Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Takeda
  2. 8.1.1 Takeda Company Information
  3. 8.1.2 Takeda Business Overview
  4. 8.1.3 Takeda Focal Segmental Glomerulosclerosis Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Takeda Focal Segmental Glomerulosclerosis Drug Product Portfolio
  6. 8.1.5 Takeda Recent Developments
  7. 8.2 GlaxoSmithKline Plc
  8. 8.2.1 GlaxoSmithKline Plc Company Information
  9. 8.2.2 GlaxoSmithKline Plc Business Overview
  10. 8.2.3 GlaxoSmithKline Plc Focal Segmental Glomerulosclerosis Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 GlaxoSmithKline Plc Focal Segmental Glomerulosclerosis Drug Product Portfolio
  12. 8.2.5 GlaxoSmithKline Plc Recent Developments
  13. 8.3 Variant Pharmaceuticals Inc
  14. 8.3.1 Variant Pharmaceuticals Inc Company Information
  15. 8.3.2 Variant Pharmaceuticals Inc Business Overview
  16. 8.3.3 Variant Pharmaceuticals Inc Focal Segmental Glomerulosclerosis Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Variant Pharmaceuticals Inc Focal Segmental Glomerulosclerosis Drug Product Portfolio
  18. 8.3.5 Variant Pharmaceuticals Inc Recent Developments
  19. 8.4 Retrophin Inc
  20. 8.4.1 Retrophin Inc Company Information
  21. 8.4.2 Retrophin Inc Business Overview
  22. 8.4.3 Retrophin Inc Focal Segmental Glomerulosclerosis Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Retrophin Inc Focal Segmental Glomerulosclerosis Drug Product Portfolio
  24. 8.4.5 Retrophin Inc Recent Developments
  25. 8.5 Dimerix Bioscience Pty Ltd
  26. 8.5.1 Dimerix Bioscience Pty Ltd Company Information
  27. 8.5.2 Dimerix Bioscience Pty Ltd Business Overview
  28. 8.5.3 Dimerix Bioscience Pty Ltd Focal Segmental Glomerulosclerosis Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Dimerix Bioscience Pty Ltd Focal Segmental Glomerulosclerosis Drug Product Portfolio
  30. 8.5.5 Dimerix Bioscience Pty Ltd Recent Developments
  31. 8.6 Complexa Inc
  32. 8.6.1 Complexa Inc Company Information
  33. 8.6.2 Complexa Inc Business Overview
  34. 8.6.3 Complexa Inc Focal Segmental Glomerulosclerosis Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Complexa Inc Focal Segmental Glomerulosclerosis Drug Product Portfolio
  36. 8.6.5 Complexa Inc Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Focal Segmental Glomerulosclerosis Drug Value Chain Analysis
  2. 9.1.1 Focal Segmental Glomerulosclerosis Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Focal Segmental Glomerulosclerosis Drug Production Mode & Process
  6. 9.2 Focal Segmental Glomerulosclerosis Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Focal Segmental Glomerulosclerosis Drug Distributors
  9. 9.2.3 Focal Segmental Glomerulosclerosis Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst